Literature DB >> 27262526

Old dogs and new tricks in antimicrobial discovery.

Mark S Butler1, Mark At Blaskovich1, Jeremy G Owen2, Matthew A Cooper3.   

Abstract

The discovery of new antibiotics is crucial if we are to avoid a future in which simple infections once again lead to death. New antibiotics were traditionally discovered by analyzing extracts from cultured soil-derived microbes. However, in the last few years only a few new antibiotic classes have been identified using this method. Attempts to apply target-based screening approaches to antibiotic discovery have also proven to be unproductive. In this article, we describe how DNA sequencing and bioinformatic techniques are revolutionizing natural product discovery leading to new natural product antibiotics sourced from both cultivated and uncultivated microbes. New chemical structures are also being 'crowd sourced' from chemists around the world, and 'forgotten' antibiotics repositioned for clinical trials after chemical or biochemical modification of the original natural product. Collectively such approaches have the potential to revamp antibiotic lead discovery and re-invigorate the antibiotic pipeline.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27262526     DOI: 10.1016/j.mib.2016.05.011

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  4 in total

Review 1.  Ribosomally synthesized and post-translationally modified peptide natural product discovery in the genomic era.

Authors:  Kenton J Hetrick; Wilfred A van der Donk
Journal:  Curr Opin Chem Biol       Date:  2017-03-02       Impact factor: 8.822

Review 2.  Omics-based natural product discovery and the lexicon of genome mining.

Authors:  Henrique Machado; Robert N Tuttle; Paul R Jensen
Journal:  Curr Opin Microbiol       Date:  2017-11-23       Impact factor: 7.934

3.  Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae.

Authors:  Bruce L Geller; Lixin Li; Fabian Martinez; Erin Sully; Carolyn R Sturge; Seth M Daly; Christine Pybus; David E Greenberg
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

4.  Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens.

Authors:  Charlotte K Hind; Christopher G Dowson; J Mark Sutton; Thomas Jackson; Melanie Clifford; R Colin Garner; Lloyd Czaplewski
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.